Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  Hangzhou Tigermed Consulting Co.,Ltd    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO.,LTD

(300347)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
11/20/2020 11/23/2020 11/24/2020 11/25/2020 11/26/2020 Date
118 117.31 117.23 114 113.33 Last
5426179 5519113 3611951 3978699 4387126 Volume
+2.25% -0.58% -0.07% -2.76% -0.59% Change
Financials
Sales 2020 3 250 M 494 M 494 M
Net income 2020 1 538 M 234 M 234 M
Net cash position 2020 12 084 M 1 838 M 1 838 M
P/E ratio 2020 61,9x
Yield 2020 0,35%
Sales 2021 4 287 M 652 M 652 M
Net income 2021 1 469 M 223 M 223 M
Net cash position 2021 12 737 M 1 937 M 1 937 M
P/E ratio 2021 64,1x
Yield 2021 0,36%
Capitalization 99 214 M 15 088 M 15 092 M
EV / Sales 2020 26,8x
EV / Sales 2021 20,2x
Nbr of Employees -
Free-Float 100,0%
More Financials
Company
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.9%); - provision of clinical research consulting services... 
Sector
Biotechnology & Medical Research
Calendar
11/26 | 02:00amShareholder meeting
More about the company
Notations Surperformance© of Hangzhou Tigermed Consulting Co.,Ltd
Trading Rating : Investor Rating :
More Ratings
All news about HANGZHOU TIGERMED CONSULTING CO.,LTD
08/30HANGZHOU TIGERMED CONSULTING : Full exercise of the over-allotment option, stabi..
PU
08/28HANGZHOU TIGERMED CONSULTING : (1) proposed partial repurchase and cancellation ..
PU
08/21HANGZHOU TIGERMED CONSULTING CO.,LTD : half-yearly earnings release
08/10HANGZHOU TIGERMED CONSULTING : 2019 Sustainability Report
PU
08/05HANGZHOU TIGERMED CONSULTING : Terms of reference for the strategy development c..
PU
08/05HANGZHOU TIGERMED CONSULTING : Terms of reference of the nomination committee of..
PU
08/05HANGZHOU TIGERMED CONSULTING : Terms of reference of the remuneration and evalua..
PU
08/05HANGZHOU TIGERMED CONSULTING : Terms of reference of the audit committee of the ..
PU
08/05HANGZHOU TIGERMED CONSULTING : Articles of association
PU
07/27HANGZHOU TIGERMED CONSULTING : China's Tigermed to raise up to $1.38 billion in ..
RE
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
RE
07/24Tigermed to raise at least $1 billion in Hong Kong deal
RE
07/24Tigermed to raise at least $1 bln in Hong Kong deal - sources
RE
06/02HANGZHOU TIGERMED CONSULTING : Tigermed Lauded by Frost & Sullivan for Its Rapid..
AQ
03/25HANGZHOU TIGERMED CONSULTING CO.,LTD : annual earnings release
More news
News in other languages on HANGZHOU TIGERMED CONSULTING CO.,LTD
08/21HANGZHOU TIGERMED CONSULTING CO.,LTD : Veröffentlichung des Halbjahresergebnisse..
08/21HANGZHOU TIGERMED CONSULTING CO.,LTD : publication des résultats semestriels
03/25HANGZHOU TIGERMED CONSULTING CO.,LTD : Veröffentlichung des Jahresergebnisses
03/25HANGZHOU TIGERMED CONSULTING CO.,LTD : publication des résultats annuels
More news
Chart HANGZHOU TIGERMED CONSULTING CO.,LTD
Duration : Period :
Hangzhou Tigermed Consulting Co.,Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO.,LTD
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Average target price 124,87 CNY
Last Close Price 113,33 CNY
Spread / Highest target 29,2%
Spread / Average Target 10,2%
Spread / Lowest Target -26,8%
EPS Revisions
Managers
NameTitle
Xiao Ping Ye Chairman & General Manager
Xiao Li Shi Chairman-Supervisory Board
Jun Gao Chief Financial Officer & Senior Vice President
Xiao Chun Cao Secretary, Director & Deputy General Manager
Zhi Min Chen Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HANGZHOU TIGERMED CONSULTING CO.,LTD79.46%15 150
LONZA GROUP AG55.66%44 931
MODERNA, INC.458.18%43 204
CELLTRION, INC.82.04%39 870
IQVIA HOLDINGS INC.9.94%32 568
SEAGEN INC.44.80%29 832